| Year |
Citation |
Score |
| 2024 |
Shin SC, Vickman RE, Filimon B, Yang Y, Hu Z, Mangold KA, Prabhakar BS, Schreiber H, Xu W. The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model. Cancer Gene Therapy. PMID 38267626 DOI: 10.1038/s41417-024-00735-1 |
0.47 |
|
| 2024 |
Wolf SP, Anastasopoulou V, Drousch K, Diehl MI, Engels B, Yew PY, Kiyotani K, Nakamura Y, Schreiber K, Schreiber H, Leisegang M. One CD4+TCR and one CD8+TCR targeting autochthonous neoantigens are essential and sufficient for tumor eradication. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38190111 DOI: 10.1158/1078-0432.CCR-23-2905 |
0.418 |
|
| 2023 |
Xu W, Shin SC, Vickman R, Filimon B, Yang Y, Hu Z, Mangold K, Prabhakar B, Schreiber H. The Safety and Efficacy of Systemic Delivery of a New Liver-de-targeted TGFβ Signaling Inhibiting Adenovirus in an Immunocompetent Triple Negative Mouse Mammary Tumor Model. Research Square. PMID 37790556 DOI: 10.21203/rs.3.rs-3317863/v1 |
0.469 |
|
| 2023 |
Ranoa DRE, Sharma P, Schane CP, Lewis AN, Valdez E, Marada VVVR, Hager MV, Montgomery W, Wolf SP, Schreiber K, Schreiber H, Bailey K, Fan TM, Hergenrother PJ, Roy EJ, et al. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. Journal For Immunotherapy of Cancer. 11. PMID 37258040 DOI: 10.1136/jitc-2022-006509 |
0.455 |
|
| 2021 |
Hu Y, Cao G, Chen X, Huang X, Asby N, Ankenbruck N, Rahman A, Thusu A, He Y, Riedell PA, Bishop MR, Schreiber H, Kline JP, Huang J. Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents. Matter. 4: 3917-3940. PMID 34901832 DOI: 10.1016/j.matt.2021.09.027 |
0.43 |
|
| 2021 |
Wolf SP, Wen FT, Schreiber H. Criteria to make animal studies more relevant to treating human cancer. Current Opinion in Immunology. 74: 25-31. PMID 34619458 DOI: 10.1016/j.coi.2021.09.002 |
0.427 |
|
| 2020 |
Sharma P, Marada VVVR, Cai Q, Kizerwetter M, He Y, Wolf SP, Schreiber K, Clausen H, Schreiber H, Kranz DM. Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides. Proceedings of the National Academy of Sciences of the United States of America. PMID 32541028 DOI: 10.1073/Pnas.1920662117 |
0.558 |
|
| 2020 |
Diehl MI, Wolf SP, Bindokas VP, Schreiber H. Automated cell cluster analysis provides insight into multi-cell-type interactions between immune cells and their targets. Experimental Cell Research. 112014. PMID 32439494 DOI: 10.1016/J.Yexcr.2020.112014 |
0.402 |
|
| 2020 |
Seth P, Xu W, Yang Y, Hu Z, Head M, Mangold KA, Sullivan M, Wang CH, Saha P, Gulukota K, Helseth DL, Guise T, Prabhakar BS, Kaul K, Schreiber H. LyP-1-modified oncolytic adenoviruses targeting transforming growth factor β inhibit tumor growth and metastases and augment immune checkpoint inhibitor therapy in breast cancer mouse models. Human Gene Therapy. PMID 32394753 DOI: 10.1089/Hum.2020.078 |
0.485 |
|
| 2020 |
Böttinger P, Schreiber K, Hyjek E, Krausz T, Spiotto MT, Steiner M, Idel C, Booras H, Beck-Engeser G, Riederer J, Willimsky G, Wolf SP, Karrison T, Jensen E, Weichselbaum RR, ... ... Schreiber H, et al. Cooperation of genes in HPV16 E6/E7-dependent cervico-vaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. Carcinogenesis. PMID 32221533 DOI: 10.1093/Carcin/Bgaa027 |
0.574 |
|
| 2020 |
Sharma P, Marada VV, Kizerwetter M, Schane CP, He Y, Wolf SP, Schreiber K, Roy EJ, Clausen H, Schreiber H, Kranz DM. Abstract 3238: Engineering chimeric antigen receptors for adoptive T cell therapy of cancers that express the Tn antigen Immunology. DOI: 10.1158/1538-7445.Am2020-3238 |
0.461 |
|
| 2019 |
Schreiber K, Karrison TG, Wolf SP, Kiyotani K, Steiner M, Littmann ER, Pamer EG, Kammertoens T, Schreiber H, Leisegang M. Impact of TCR diversity on the development of transplanted or chemically induced tumors. Cancer Immunology Research. PMID 31831634 DOI: 10.1158/2326-6066.Cir-19-0567 |
0.557 |
|
| 2019 |
He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, ... ... Schreiber H, et al. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. Jci Insight. 4. PMID 31801912 DOI: 10.1172/jci.insight.135306 |
0.321 |
|
| 2019 |
He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, ... ... Schreiber H, et al. Multiple cancer-specific antigens are targeted by a chimeric antibody receptor on a single cancer cell. Jci Insight. 4. PMID 31672936 DOI: 10.1172/Jci.Insight.130416 |
0.539 |
|
| 2019 |
Friedman J, Moore EC, Zolkind P, Robbins Y, Clavijo PE, Sun L, Greene S, Morisada MV, Mydlarz WK, Schmitt N, Hodge JW, Schreiber H, Van Waes C, Uppaluri R, Allen C. Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor-antigen specific T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31645352 DOI: 10.1158/1078-0432.Ccr-19-2209 |
0.499 |
|
| 2019 |
Steentoft C, Fuhrmann M, Battisti F, Van Coillie J, Madsen TD, Campos D, Halim A, Vakhrushev SY, Joshi H, Schreiber H, Mandel U, Narimatsu Y. A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody. Glycobiology. PMID 30726901 DOI: 10.1093/Glycob/Cwz004 |
0.439 |
|
| 2019 |
Schreiber H. Fibroblasts: Dangerous travel companions. The Journal of Experimental Medicine. PMID 30710056 DOI: 10.1084/Jem.20181850 |
0.312 |
|
| 2019 |
Rosenberg JN, Cao G, Borja-Prieto F, He Y, Schreiber H, Huang J. Abstract 488: Direct real-time visualization and quantification of T cell receptor dynamics Immunology. DOI: 10.1158/1538-7445.Sabcs18-488 |
0.315 |
|
| 2019 |
Wolf S, Schreiber K, Steiner M, Weichselbaum R, Leisegang M, Schreiber H. E-102 Destruction of the tumor microenvironment by neoantigen-specific T cells prevents relapse of therapy-resistant cancer variants Jaids Journal of Acquired Immune Deficiency Syndromes. 81: 41. DOI: 10.1097/01.Qai.0000557968.71935.Dc |
0.553 |
|
| 2018 |
Leisegang M, Schreiber K, Wolf SP, Anastosopolou V, Borutta K, Yew P, Kiyotani K, Nakamura Y, Schreiber H. Abstract 3587: TCR-transduced T cells targeting a truncal mutation caused by a nsSNV destroy large solid tumors despite intratumoral genetic heterogeneity Cancer Research. 78: 3587-3587. DOI: 10.1158/1538-7445.Am2018-3587 |
0.546 |
|
| 2017 |
Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, Sommermeyer D, Engels B, Leisegang M, Textor A, Joerg Fehling H, ... ... Schreiber H, et al. Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature. PMID 28445461 DOI: 10.1038/Nature22311 |
0.378 |
|
| 2017 |
Arina A, Karrison TG, Galka E, Schreiber K, Weichselbaum RR, Schreiber H. Transfer of allogeneic CD4+ T cells rescues CD8+ T cells in anti-PD-L1-resistant tumors leading to tumor eradication. Cancer Immunology Research. PMID 28077434 DOI: 10.1158/2326-6066.Cir-16-0293 |
0.608 |
|
| 2017 |
Matsuda T, Kato T, Ikeda Y, Leisegang M, Yoshimura S, Hikichi T, Harada M, Zewde M, Park J, Schreiber H, Kiyotani K, Nakamura Y. Abstract 625: Eradication of cancer cells by T-cell receptor-engineered T cells targeting neoantigens/oncoantigens Cancer Research. 77: 625-625. DOI: 10.1158/1538-7445.Am2017-625 |
0.485 |
|
| 2016 |
Binder DC, Arina A, Wen F, Tu T, Zhao M, Hoffman RM, Wainwright DA, Schreiber H. Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium. Oncoimmunology. 5: e1130207. PMID 27471609 DOI: 10.1080/2162402X.2015.1130207 |
0.812 |
|
| 2016 |
Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, Cogdill AP, Chen TJ, Song D, Scholler J, Kranz DM, ... ... Schreiber H, et al. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 44: 1444-1454. PMID 27332733 DOI: 10.1016/J.Immuni.2016.05.014 |
0.602 |
|
| 2016 |
Arina A, Idel C, Hyjek EM, Alegre ML, Wang Y, Bindokas VP, Weichselbaum RR, Schreiber H. Tumor-associated fibroblasts predominantly come from local and not circulating precursors. Proceedings of the National Academy of Sciences of the United States of America. PMID 27317748 DOI: 10.1073/Pnas.1600363113 |
0.587 |
|
| 2015 |
Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, Arina A, Duraiswamy J, Weichselbaum RR, Uckert W, Nakamura Y, Schreiber H. Eradication of large solid tumors by gene therapy with a T cell receptor targeting a single cancer-specific point mutation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26667491 DOI: 10.1158/1078-0432.Ccr-15-2361 |
0.59 |
|
| 2015 |
Blankenstein T, Leisegang M, Uckert W, Schreiber H. Targeting cancer-specific mutations by T cell receptor gene therapy. Current Opinion in Immunology. 33: 112-9. PMID 25728991 DOI: 10.1016/J.Coi.2015.02.005 |
0.483 |
|
| 2014 |
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, ... ... Schreiber H, et al. Classification of current anticancer immunotherapies. Oncotarget. 5: 12472-508. PMID 25537519 DOI: 10.18632/Oncotarget.2998 |
0.497 |
|
| 2014 |
Binder DC, Schreiber H. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. Cancer Research. 74: 632; discussion 635. PMID 24408925 DOI: 10.1158/0008-5472.Can-13-2216 |
0.758 |
|
| 2014 |
Arina A, Schreiber K, Binder DC, Karrison TG, Liu RB, Schreiber H. Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. Journal of Immunology (Baltimore, Md. : 1950). 192: 1286-93. PMID 24367029 DOI: 10.4049/Jimmunol.1202498 |
0.823 |
|
| 2014 |
Binder DC, Wen F, Arina A, Tu T, Zhao M, Hoffman RM, Schreiber H. Effect of adoptive T-cell therapy and intratumoral heat-killed bacteria on large tumors. Journal of Clinical Oncology. 32: 11112-11112. DOI: 10.1200/Jco.2014.32.15_Suppl.11112 |
0.829 |
|
| 2013 |
Binder DC, Schreiber H. High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies. Oncoimmunology. 2: e26704. PMID 24563823 DOI: 10.4161/Onci.26704 |
0.739 |
|
| 2013 |
Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, Piston DW, Pittet MJ, Lin PC, Zal T, Schreiber H. Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. Oncoimmunology. 2: e26677. PMID 24482750 DOI: 10.4161/Onci.26677 |
0.639 |
|
| 2013 |
Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, Karrison T, Burnette B, Idel C, Zhao M, Hoffman RM, Munn DH, Rowley DA, Schreiber H. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunology Research. 1: 123-33. PMID 24455752 DOI: 10.1158/2326-6066.Cir-13-0058 |
0.808 |
|
| 2013 |
Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology. 14: 1014-22. PMID 24048123 DOI: 10.1038/Ni.2703 |
0.616 |
|
| 2013 |
Liu RB, Engels B, Schreiber K, Ciszewski C, Schietinger A, Schreiber H, Jabri B. IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proceedings of the National Academy of Sciences of the United States of America. 110: 8158-63. PMID 23637340 DOI: 10.1073/Pnas.1301022110 |
0.571 |
|
| 2013 |
Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA, Schreiber H. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 23: 516-26. PMID 23597565 DOI: 10.1016/J.Ccr.2013.03.018 |
0.75 |
|
| 2013 |
Chervin AS, Stone JD, Soto CM, Engels B, Schreiber H, Roy EJ, Kranz DM. Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Therapy. 20: 634-44. PMID 23052828 DOI: 10.1038/Gt.2012.80 |
0.583 |
|
| 2013 |
Soto CM, Stone JD, Chervin AS, Engels B, Schreiber H, Roy EJ, Kranz DM. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunology, Immunotherapy : Cii. 62: 359-69. PMID 22926060 DOI: 10.1007/S00262-012-1336-Z |
0.57 |
|
| 2012 |
Engels B, Chervin AS, Sant AJ, Kranz DM, Schreiber H. Long-term Persistence of CD4(+) but Rapid Disappearance of CD8(+) T Cells Expressing an MHC Class I-restricted TCR of Nanomolar Affinity. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 652-660. PMID 28160633 DOI: 10.1038/mt.2011.286 |
0.34 |
|
| 2012 |
Stone JD, Aggen DH, Schietinger A, Schreiber H, Kranz DM. A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology. 1: 863-873. PMID 23162754 DOI: 10.4161/Onci.20592 |
0.53 |
|
| 2012 |
Stone JD, Chervin AS, Schreiber H, Kranz DM. Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor. Biotechnology Progress. 28: 1588-97. PMID 22961781 DOI: 10.1002/Btpr.1631 |
0.4 |
|
| 2012 |
Wen FT, Thisted RA, Rowley DA, Schreiber H. A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology. 1: 172-178. PMID 22720238 DOI: 10.4161/Onci.1.2.18311 |
0.584 |
|
| 2012 |
Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A, Karrison TG, Weichselbaum RR, Rowley DA, Schreiber H. Spleen cells from young but not old immunized mice eradicate large established cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2526-33. PMID 22415314 DOI: 10.1158/1078-0432.Ccr-12-0127 |
0.776 |
|
| 2012 |
Liu RB, Engels B, Arina A, Schreiber K, Hyjek E, Schietinger A, Binder DC, Butz E, Krausz T, Rowley DA, Jabri B, Schreiber H. Densely granulated murine NK cells eradicate large solid tumors. Cancer Research. 72: 1964-74. PMID 22374983 DOI: 10.1158/0008-5472.Can-11-3208 |
0.782 |
|
| 2012 |
Engels B, Chervin AS, Sant AJ, Kranz DM, Schreiber H. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 652-60. PMID 22233579 DOI: 10.1038/Mt.2011.286 |
0.447 |
|
| 2012 |
Engels B, Rowley DA, Schreiber H. Targeting stroma to treat cancers. Seminars in Cancer Biology. 22: 41-9. PMID 22212863 DOI: 10.1016/J.Semcancer.2011.12.008 |
0.495 |
|
| 2012 |
Aggen DH, Chervin AS, Schmitt TM, Engels B, Stone JD, Richman SA, Piepenbrink KH, Baker BM, Greenberg PD, Schreiber H, Kranz DM. Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains. Gene Therapy. 19: 365-74. PMID 21753797 DOI: 10.1038/Gt.2011.104 |
0.431 |
|
| 2012 |
Rowley DA, Schreiber K, Schreiber H. Spleen cells from young donors eradicate large tumors-response Clinical Cancer Research. 18: 6076. DOI: 10.1158/1078-0432.Ccr-12-2816 |
0.51 |
|
| 2011 |
Schreiber H, Rowley JD, Rowley DA. Targeting mutations predictably. Blood. 118: 830-1. PMID 21799095 DOI: 10.1182/Blood-2011-06-357541 |
0.304 |
|
| 2011 |
Wu TH, Schreiber K, Arina A, Khodarev NN, Efimova EV, Rowley DA, Weichselbaum RR, Schreiber H. Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. Cancer Immunity. 11: 2. PMID 21714479 |
0.827 |
|
| 2010 |
Schreiber H, Rowley DA. Cancer. Awakening immunity. Science (New York, N.Y.). 330: 761-2. PMID 21051618 DOI: 10.1126/Science.1198345 |
0.35 |
|
| 2010 |
Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. The Journal of Experimental Medicine. 207: 2469-77. PMID 20921286 DOI: 10.1084/Jem.20092450 |
0.548 |
|
| 2010 |
Brooks CL, Schietinger A, Borisova SN, Kufer P, Okon M, Hirama T, Mackenzie CR, Wang LX, Schreiber H, Evans SV. Antibody recognition of a unique tumor-specific glycopeptide antigen. Proceedings of the National Academy of Sciences of the United States of America. 107: 10056-61. PMID 20479270 DOI: 10.1073/Pnas.0915176107 |
0.516 |
|
| 2010 |
Philip M, Schietinger A, Schreiber H. Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells. Immunology. 130: 494-503. PMID 20331471 DOI: 10.1111/J.1365-2567.2010.03258.X |
0.428 |
|
| 2009 |
Thomas DL, Kim M, Bowerman NA, Narayanan S, Kranz DM, Schreiber H, Roy EJ. Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells. Journal of Immunology (Baltimore, Md. : 1950). 183: 1828-37. PMID 19592642 DOI: 10.4049/Jimmunol.0802322 |
0.636 |
|
| 2008 |
Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. The Journal of Clinical Investigation. 118: 3574-81. PMID 18982164 DOI: 10.1172/Jci36049 |
0.344 |
|
| 2008 |
Schreiber H. Tumor-specific immune responses. Seminars in Immunology. 20: 265-6. PMID 18977672 DOI: 10.1016/J.Smim.2008.10.001 |
0.623 |
|
| 2008 |
Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy. Seminars in Immunology. 20: 276-85. PMID 18684640 DOI: 10.1016/J.Smim.2008.07.001 |
0.646 |
|
| 2008 |
Zhang B, Karrison T, Rowley DA, Schreiber H. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. The Journal of Clinical Investigation. 118: 1398-404. PMID 18317595 DOI: 10.1172/Jci33522 |
0.627 |
|
| 2008 |
Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Research. 68: 1563-71. PMID 18316622 DOI: 10.1158/0008-5472.Can-07-5324 |
0.683 |
|
| 2008 |
Schreiber H, Rowley DA. Cancer. Quo vadis, specificity? Science (New York, N.Y.). 319: 164-5. PMID 18187644 DOI: 10.1126/Science.1153713 |
0.549 |
|
| 2007 |
Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF, Schreiber H, You Z, Kaynor C, Wang X, Fu YX. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. Journal of Immunology (Baltimore, Md. : 1950). 179: 1960-8. PMID 17641063 DOI: 10.4049/Jimmunol.179.3.1960 |
0.594 |
|
| 2007 |
Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. The Journal of Experimental Medicine. 204: 49-55. PMID 17210731 DOI: 10.1084/Jem.20062056 |
0.77 |
|
| 2007 |
Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Research. 67: 425; author reply 42. PMID 17210725 DOI: 10.1158/0008-5472.Can-06-3037 |
0.379 |
|
| 2006 |
Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, Schreiber H. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science (New York, N.Y.). 314: 304-8. PMID 17038624 DOI: 10.1126/Science.1129200 |
0.516 |
|
| 2006 |
Schreiber K, Rowley DA, Riethmüller G, Schreiber H. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematology/Oncology Clinics of North America. 20: 567-84. PMID 16762725 DOI: 10.1016/J.Hoc.2006.03.001 |
0.506 |
|
| 2006 |
Spiotto MT, Schreiber H. Floxed reporter genes: Flow-cytometric selection of clonable cells expressing high levels of a target gene after tamoxifen-regulated Cre-loxP recombination. Journal of Immunological Methods. 312: 201-8. PMID 16674971 DOI: 10.1016/J.Jim.2006.02.016 |
0.575 |
|
| 2006 |
Lodge A, Yu P, Nicholl MB, Brown IE, Jackson CC, Schreiber K, Sugg SL, Schreiber H, Shilyansky J. CD40 ligation restores cytolytic T lymphocyte response and eliminates fibrosarcoma in the peritoneum of mice lacking CD4+ T cells. Cancer Immunology, Immunotherapy : Cii. 55: 1542-52. PMID 16491399 DOI: 10.1007/S00262-006-0147-5 |
0.487 |
|
| 2006 |
Yu P, Rowley DA, Fu YX, Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Current Opinion in Immunology. 18: 226-31. PMID 16459066 DOI: 10.1016/J.Coi.2006.01.004 |
0.601 |
|
| 2005 |
Spiotto MT, Schreiber H. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immunity. 5: 8. PMID 15934727 |
0.71 |
|
| 2005 |
Kaplan BL, Moore TV, Schreiber K, Callender GG, Schreiber H, Nishimura MI. A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity. Cancer Letters. 224: 153-66. PMID 15911111 DOI: 10.1016/J.Canlet.2004.11.035 |
0.481 |
|
| 2005 |
Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. The Journal of Experimental Medicine. 201: 779-91. PMID 15753211 DOI: 10.1084/Jem.20041684 |
0.602 |
|
| 2004 |
Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Seminars in Cancer Biology. 14: 433-9. PMID 15489136 DOI: 10.1016/J.Semcancer.2004.06.006 |
0.347 |
|
| 2004 |
Schreiber K, Cannon RE, Karrison T, Beck-Engeser G, Huo D, Tennant RW, Jensen H, Kast WM, Krausz T, Meredith SC, Chen L, Schreiber H. Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene. 23: 3972-9. PMID 15077191 DOI: 10.1038/Sj.Onc.1207507 |
0.349 |
|
| 2004 |
Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nature Medicine. 10: 294-8. PMID 14981514 DOI: 10.1038/Nm999 |
0.773 |
|
| 2004 |
Wu TH, Pabin CN, Qin Z, Blankenstein T, Philip M, Dignam J, Schreiber K, Schreiber H. Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18. Journal of Immunology (Baltimore, Md. : 1950). 172: 3243-51. PMID 14978132 DOI: 10.4049/Jimmunol.172.5.3243 |
0.762 |
|
| 2004 |
Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX. Priming of naive T cells inside tumors leads to eradication of established tumors. Nature Immunology. 5: 141-9. PMID 14704792 DOI: 10.1038/Ni1029 |
0.634 |
|
| 2003 |
Spiotto MT, Fu YX, Schreiber H. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Current Opinion in Immunology. 15: 725-30. PMID 14630209 DOI: 10.1016/J.Coi.2003.09.018 |
0.755 |
|
| 2003 |
Spiotto MT, Reth MA, Schreiber H. Genetic changes occurring in established tumors rapidly stimulate new antibody responses. Proceedings of the National Academy of Sciences of the United States of America. 100: 5425-30. PMID 12702750 DOI: 10.1073/Pnas.0930140100 |
0.754 |
|
| 2003 |
Yu P, Spiotto MT, Lee Y, Schreiber H, Fu YX. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. The Journal of Experimental Medicine. 197: 985-95. PMID 12695490 DOI: 10.1084/Jem.20021804 |
0.742 |
|
| 2003 |
Beck C, Schreiber K, Schreiber H, Rowley DA. C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum. European Journal of Immunology. 33: 19-28. PMID 12594828 DOI: 10.1002/Immu.200390003 |
0.601 |
|
| 2002 |
Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 17: 737-47. PMID 12479820 DOI: 10.1016/S1074-7613(02)00480-6 |
0.762 |
|
| 2002 |
Schreiber H, Wu TH, Nachman J, Kast WM. Immunodominance and tumor escape. Seminars in Cancer Biology. 12: 25-31. PMID 11926408 DOI: 10.1006/Scbi.2001.0401 |
0.823 |
|
| 2001 |
Beck-Engeser GB, Monach PA, Mumberg D, Yang F, Wanderling S, Schreiber K, Espinosa R, Le Beau MM, Meredith SC, Schreiber H. Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens. The Journal of Experimental Medicine. 194: 285-300. PMID 11489948 DOI: 10.1084/Jem.194.3.285 |
0.579 |
|
| 2001 |
Weijzen S, Meredith SC, Velders MP, Elmishad AG, Schreiber H, Kast WM. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide Journal of Immunology. 166: 7151-7157. PMID 11390461 DOI: 10.4049/Jimmunol.166.12.7151 |
0.328 |
|
| 2001 |
Schreiber K, Wu TH, Kast WM, Schreiber H. Tracking the common ancestry of antigenically distinct cancer variants. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 871s-875s. PMID 11300485 |
0.82 |
|
| 2001 |
Beck C, Schreiber H, Rowley DA. Role of TGF-? in immune-evasion of cancer Microscopy Research and Technique. 52: 387-395. PMID 11170297 DOI: 10.1002/1097-0029(20010215)52:4<387::Aid-Jemt1023>3.0.Co;2-W |
0.432 |
|
| 2000 |
Schreiber H, Wu TH, Nachman J, Rowley DA. Immunological enhancement of primary tumor development and its prevention. Seminars in Cancer Biology. 10: 351-7. PMID 11100883 DOI: 10.1006/Scbi.2000.0331 |
0.816 |
|
| 2000 |
Loukinova E, Dong G, Enamorado-Ayalya I, Thomas GR, Chen Z, Schreiber H, Van Waes C. Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene. 19: 3477-86. PMID 10918606 DOI: 10.1038/Sj.Onc.1203687 |
0.398 |
|
| 2000 |
Siegel CT, Schreiber K, Meredith SC, Beck-Engeser GB, Lancki DW, Lazarski CA, Fu YX, Rowley DA, Schreiber H. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. The Journal of Experimental Medicine. 191: 1945-56. PMID 10839809 DOI: 10.1084/Jem.191.11.1945 |
0.465 |
|
| 1999 |
Zierhut M, Streilein JW, Schreiber H, Jager MJ, Ruiter D, Ksander BR. Immunology of ocular tumours. Immunology Today. 20: 482-5. PMID 10529773 DOI: 10.1016/S0167-5699(99)01513-3 |
0.589 |
|
| 1999 |
Seetharam S, Staba MJ, Schumm LP, Schreiber K, Schreiber H, Kufe DW, Weichselbaum RR. Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. International Journal of Oncology. 15: 769-73. PMID 10493960 DOI: 10.3892/Ijo.15.4.769 |
0.465 |
|
| 1999 |
Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ Proceedings of the National Academy of Sciences of the United States of America. 96: 8633-8638. PMID 10411927 DOI: 10.1073/Pnas.96.15.8633 |
0.594 |
|
| 1998 |
Flood PM, Liu X, Alexander R, Schreiber H, Haque S. Loss of resistance to a highly immunogenic tumor with age corresponds to the decline of CD8 T cell activity. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 307-16. PMID 9672852 DOI: 10.1097/00002371-199807000-00008 |
0.524 |
|
| 1998 |
Dubey P, Meredith SC, Siegel CT, Schreiber H. Tumor cells induce cytolytic T cells to a single immunodominant mutant peptide. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 277-82. PMID 9672849 DOI: 10.1097/00002371-199807000-00005 |
0.658 |
|
| 1997 |
Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. The Journal of Experimental Medicine. 186: 229-38. PMID 9221752 DOI: 10.1084/Jem.186.2.229 |
0.676 |
|
| 1997 |
Dubey P, Hendrickson RC, Meredith SC, Siegel CT, Shabanowitz J, Skipper JC, Engelhard VH, Hunt DF, Schreiber H. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. The Journal of Experimental Medicine. 185: 695-705. PMID 9034148 DOI: 10.1084/Jem.185.4.695 |
0.558 |
|
| 1997 |
Mumberg D, Wick M, Schreiber H. Unique tumor antigens redefined as mutant tumor-specific antigens. Seminars in Immunology. 8: 289-93. PMID 8956457 DOI: 10.1006/Smim.1996.0037 |
0.653 |
|
| 1996 |
Van Waes C, Monach PA, Urban JL, Wortzel RD, Schreiber H. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens. 47: 399-407. PMID 8795140 DOI: 10.1111/J.1399-0039.1996.Tb02575.X |
0.632 |
|
| 1996 |
Seung LP, Weichselbaum RR, Toledano A, Schreiber K, Schreiber H. Radiation Can Inhibit Tumor Growth Indirectly while Depleting Circulating Leukocytes Radiation Research. 146: 612. DOI: 10.2307/3579376 |
0.58 |
|
| 1995 |
Pekarek LA, Starr BA, Toledano AY, Schreiber H. Inhibition of tumor growth by elimination of granulocytes Journal of Experimental Medicine. 181: 435-440. PMID 7807024 DOI: 10.1084/Jem.181.1.435 |
0.616 |
|
| 1995 |
Seung LP, Rowley DA, Dubey P, Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proceedings of the National Academy of Sciences of the United States of America. 92: 6254-8. PMID 7603979 DOI: 10.1073/Pnas.92.14.6254 |
0.595 |
|
| 1995 |
Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity. 2: 45-59. PMID 7600302 DOI: 10.1016/1074-7613(95)90078-0 |
0.567 |
|
| 1993 |
Teng MN, Turksen K, Jacobs CA, Fuchs E, Schreiber H. Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein Clinical Immunology and Immunopathology. 69: 215-222. PMID 8403559 DOI: 10.1006/Clin.1993.1172 |
0.344 |
|
| 1993 |
Seung S, Urban JL, Schreiber H. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. The Journal of Experimental Medicine. 178: 933-40. PMID 8394406 DOI: 10.1084/Jem.178.3.933 |
0.604 |
|
| 1993 |
Koeppen H, Singh S, Schreiber H. Genetically engineered vaccines. Comparison of active versus passive immunotherapy against solid tumors. Annals of the New York Academy of Sciences. 690: 244-55. PMID 8368742 DOI: 10.1111/J.1749-6632.1993.Tb44013.X |
0.609 |
|
| 1993 |
Koeppen H, Acena M, Drolet A, Rowley DA, Schreiber H. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes. European Journal of Immunology. 23: 2770-6. PMID 8223853 DOI: 10.1002/Eji.1830231108 |
0.643 |
|
| 1993 |
Koeppen HK, Singh S, Stauss HJ, Park BH, Rowley DA, Schreiber H. CD4-positive and B lymphocytes in transplantation immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes. Transplantation. 55: 1349-55. PMID 8100089 DOI: 10.1097/00007890-199306000-00026 |
0.542 |
|
| 1993 |
Moach PA, Schreiber H, Rowley DA. CD4+ and B lymphocytes in transplantation immunity. II: Augmented rejection of tumor allografts by mice lacking B cells Transplantation. 55: 1356-1360. DOI: 10.1097/00007890-199306000-00027 |
0.448 |
|
| 1992 |
Blankenstein T, Rowley DA, Schreiber H. Cytokines and cancer: experimental systems. Current Opinion in Immunology. 3: 694-8. PMID 1755987 DOI: 10.1016/0952-7915(91)90098-L |
0.6 |
|
| 1992 |
Urban JL, Schreiber H. Tumor antigens. Annual Review of Immunology. 10: 617-44. PMID 1590998 DOI: 10.1146/annurev.iy.10.040192.003153 |
0.539 |
|
| 1992 |
Singh S, Ross SR, Acena M, Rowley DA, Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. The Journal of Experimental Medicine. 175: 139-46. PMID 1309851 DOI: 10.1084/Jem.175.1.139 |
0.535 |
|
| 1991 |
Teng MN, Park BH, Koeppen HK, Tracey KJ, Fendly BM, Schreiber H. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proceedings of the National Academy of Sciences of the United States of America. 88: 3535-9. PMID 2023898 DOI: 10.1073/Pnas.88.9.3535 |
0.593 |
|
| 1990 |
Schreiber H, Koeppen H, Ward PL. Tumor-specific antigens and tumor-specific mutant proteins in mouse and man. Haematology and Blood Transfusion. 32: 284-8. PMID 2483150 DOI: 10.1007/978-3-642-74621-5_50 |
0.622 |
|
| 1990 |
Perdrizet GA, Ross SR, Stauss HJ, Singh S, Koeppen H, Schreiber H. Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. The Journal of Experimental Medicine. 171: 1205-20. PMID 2324687 DOI: 10.1084/Jem.171.4.1205 |
0.55 |
|
| 1990 |
Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proceedings of the National Academy of Sciences of the United States of America. 87: 1486-90. PMID 2137615 DOI: 10.1073/Pnas.87.4.1486 |
0.478 |
|
| 1989 |
Ward PL, Koeppen H, Hurteau T, Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. The Journal of Experimental Medicine. 170: 217-32. PMID 2787379 DOI: 10.1084/Jem.170.1.217 |
0.644 |
|
| 1989 |
Mullen CA, Rowley DA, Schreiber H. Highly immunogenic regressor tumor cells can prevent development of postsurgical tumor immunity. Cellular Immunology. 119: 101-13. PMID 2522025 DOI: 10.1016/0008-8749(89)90227-X |
0.621 |
|
| 1988 |
Rothstein JL, Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proceedings of the National Academy of Sciences of the United States of America. 85: 607-11. PMID 3422444 DOI: 10.1073/Pnas.85.2.607 |
0.364 |
|
| 1988 |
Schreiber H, Ward PL, Rowley DA, Stauss HJ. Unique tumor-specific antigens. Annual Review of Immunology. 6: 465-83. PMID 3289573 DOI: 10.1146/Annurev.Iy.06.040188.002341 |
0.627 |
|
| 1988 |
Urban JL, Schreiber H. Host-tumor interactions in immunosurveillance against cancer. Progress in Experimental Tumor Research. 32: 17-68. PMID 3287449 DOI: 10.1159/000414673 |
0.377 |
|
| 1988 |
Ellenhorn JD, Hirsch R, Schreiber H, Bluestone JA. In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science (New York, N.Y.). 242: 569-71. PMID 2902689 DOI: 10.1126/Science.2902689 |
0.566 |
|
| 1987 |
Philipps C, Stauss HJ, Wortzel RD, Schreiber H. A novel MHC class I molecule as a tumour-specific antigen. Correlation between the antibody-defined and the CTL-defined target structure. Journal of Immunogenetics. 13: 93-9. PMID 3493299 DOI: 10.1111/J.1744-313X.1986.Tb01089.X |
0.419 |
|
| 1987 |
Urban JL, Rothstein JL, Shephard MH, Schreiber H. Tumor necrosis factor: a potent mediator of macrophage-dependent tumor-cell killing. Haematology and Blood Transfusion. 31: 351-4. PMID 3443399 DOI: 10.1007/978-3-642-72624-8_73 |
0.604 |
|
| 1987 |
Stauss HJ, Fink MA, Starr B, Schreiber H. Identification of a gene encoding a tumor-specific antigen that causes tumor rejection Hamatologie Und Bluttransfusion. 31: 308-313. PMID 3443398 DOI: 10.1007/978-3-642-72624-8_65 |
0.619 |
|
| 1986 |
Stauss HJ, Van Waes C, Fink MA, Starr B, Schreiber H. Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer. The Journal of Experimental Medicine. 164: 1516-30. PMID 3490532 DOI: 10.1084/Jem.164.5.1516 |
0.601 |
|
| 1986 |
Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proceedings of the National Academy of Sciences of the United States of America. 83: 5233-7. PMID 3487788 DOI: 10.1073/Pnas.83.14.5233 |
0.49 |
|
| 1986 |
Van Waes C, Urban JL, Rothstein JL, Ward PL, Schreiber H. Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells. The Journal of Experimental Medicine. 164: 1547-65. PMID 2945891 DOI: 10.1084/Jem.164.5.1547 |
0.632 |
|
| 1986 |
Stauss HJ, Linsk R, Fischer A, Watts S, Banasiak D, Haberman A, Clark I, Forman J, McMillan M, Schreiber H. Isolation of the MHC genes encoding the tumour-specific class I antigens expressed on a murine fibrosarcoma. Journal of Immunogenetics. 13: 101-11. PMID 2880914 DOI: 10.1111/J.1744-313X.1986.Tb01090.X |
0.307 |
|
| 1985 |
Mullen CA, Urban JL, Van Waes C, Rowley DA, Schreiber H. Multiple cancers. Tumor burden permits the outgrowth of other cancers. The Journal of Experimental Medicine. 162: 1665-82. PMID 3877140 DOI: 10.1084/Jem.162.5.1665 |
0.646 |
|
| 1985 |
Philipps C, McMillan M, Flood PM, Murphy DB, Forman J, Lancki D, Womack JE, Goodenow RS, Schreiber H. Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule. Proceedings of the National Academy of Sciences of the United States of America. 82: 5140-4. PMID 3860848 DOI: 10.1073/Pnas.82.15.5140 |
0.613 |
|
| 1984 |
Urban J, Schreiber H. Surveillance role of various leukocytes in preventing the outgrowth of potentially malignant cells. Contemporary Topics in Immunobiology. 13: 225-42. PMID 6610532 DOI: 10.1007/978-1-4757-1445-6_11 |
0.489 |
|
| 1984 |
Wortzel RD, Urban JL, Schreiber H. Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines. Proceedings of the National Academy of Sciences of the United States of America. 81: 2186-90. PMID 6609361 DOI: 10.1073/Pnas.81.7.2186 |
0.622 |
|
| 1984 |
Urban JL, Van Waes C, Schreiber H. Pecking order among tumor-specific antigens. European Journal of Immunology. 14: 181-7. PMID 6230244 DOI: 10.1002/Eji.1830140214 |
0.642 |
|
| 1984 |
Schreiber H. Idiotype network interactions in tumor immunity. Advances in Cancer Research. 41: 291-321. PMID 6203338 DOI: 10.1016/S0065-230X(08)60019-6 |
0.595 |
|
| 1983 |
Wortzel RD, Philipps C, Schreiber H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature. 304: 165-167. PMID 6602947 DOI: 10.1038/304165A0 |
0.405 |
|
| 1983 |
Wortzel RD, Philipps C, Urban JL, Schreiber H. Dissection of a unique tumor-specific transplantation antigen into multiple unique independent epitopes using syngeneic T-cell lines. Haematology and Blood Transfusion. 28: 489-92. PMID 6602751 DOI: 10.1007/978-3-642-68761-7_96 |
0.648 |
|
| 1983 |
Urban JL, Schreiber H. Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity. The Journal of Experimental Medicine. 157: 642-56. PMID 6185615 DOI: 10.1084/Jem.157.2.642 |
0.649 |
|
| 1982 |
Urban JL, Holland JM, Kripke ML, Schreiber H. Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation Journal of Experimental Medicine. 156: 1025-1041. PMID 7153707 DOI: 10.1084/Jem.156.4.1025 |
0.594 |
|
| 1982 |
Urban JL, Burton RC, Holland JM, Kripke ML, Schreiber H. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. The Journal of Experimental Medicine. 155: 557-73. PMID 6977009 DOI: 10.1084/Jem.155.2.557 |
0.654 |
|
| 1982 |
Urban J, Schreiber H. Interrelationship Between Nk Activity And T Cell-Mediated Immunity In Syngeneic Tumor Rejection Nk Cells and Other Natural Effector Cells. 1393-1398. DOI: 10.1016/B978-0-12-341360-4.50205-5 |
0.634 |
|
| 1981 |
Schreiber H, Flood PM, Kripke ML, Urban JL. Modulation of growth of malignant cells by anti-idiotypic immunity Hamatologie Und Bluttransfusion. 26: 368-371. PMID 6976294 DOI: 10.1007/978-3-642-67984-1_67 |
0.38 |
|
| 1981 |
Flood PM, Urban JL, Kripke ML, Schreiber H. Loss of tumor-specific and idiotype-specific immunity with age Journal of Experimental Medicine. 154: 275-290. PMID 6973599 DOI: 10.1084/Jem.154.2.275 |
0.547 |
|
| 1980 |
Flood PM, Kripke ML, Rowley DA, Schreiber H. Suppression of tumor rejection by autologous anti-idiotypic immunity Proceedings of the National Academy of Sciences of the United States of America. 77: 2209-2213. PMID 6966405 DOI: 10.1073/Pnas.77.4.2209 |
0.653 |
|
| 1980 |
Benca R, Quintáns J, Kearney JF, Flood PM, Schreiber H. Studies on phosphorylcholine-specific T cell idiotypes and idiotype-specific immunity Molecular Immunology. 17: 823-831. PMID 6163967 DOI: 10.1016/0161-5890(80)90031-0 |
0.433 |
|
| 1980 |
Loken MR, Leibson PJ, Schreiber H. Heritable and non-heritable variations in the phenotype of myeloma cells as detected by a fluorescence-activated cell sorter. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 27: 1647-8. PMID 521620 DOI: 10.1177/27.12.521620 |
0.316 |
|
| 1979 |
Reale FR, Bartels PH, Bibbo M, Chen M, Schreiber H, Sychra JJ, Wied GL. Differentiation by TICAS analysis of cell populations of tracheal aspirates from hamsters with squamous-cell carcinoma. American Journal of Clinical Pathology. 72: 52-8. PMID 453111 DOI: 10.1093/Ajcp/72.1.52 |
0.332 |
|
| 1979 |
Leibson PJ, Loken MR, Panem S, Schreiber H. Clonal evolution of myeloma cells leads to quantitative changes in immunoglobulin secretion and surface antigen expression. Proceedings of the National Academy of Sciences of the United States of America. 76: 2937-41. PMID 288078 DOI: 10.1073/Pnas.76.6.2937 |
0.42 |
|
| 1979 |
Leibson PJ, Schreiber H, Loken MR, Panem S, Rowley DA. Time-dependent resistance or susceptibility of tumor cells to cytotoxic antibody after exposure to a chemotherapeutic agent. Proceedings of the National Academy of Sciences of the United States of America. 75: 6202-6. PMID 216016 DOI: 10.1073/Pnas.75.12.6202 |
0.558 |
|
| 1976 |
Rowley DA, Köhler H, Schreiber H, Kaye ST, Lorbach I. Suppression by autogenous complementary idiotypes: the priority of the first response. The Journal of Experimental Medicine. 144: 946-59. PMID 62017 DOI: 10.1084/Jem.144.4.946 |
0.414 |
|
| 1975 |
Schreiber H, Schreiber K, Martin DH. Experimental tumor induction in a circumscribed region of the hamster trachea: correlation of histology and exfoliative cytology. Journal of the National Cancer Institute. 54: 187-97. PMID 1113300 DOI: 10.1093/Jnci/54.1.187 |
0.463 |
|
| Show low-probability matches. |